Diamond Equity Research LLC is being compensated by Chimeric Therapeutics Limited for producing research materials regarding Chimeric Therapeutics Limited and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. All payments are received upfront and are billed for research engagement. As of 09/10/2021 the issuer had paid us $20,000 for our services, consisting of $20,000 for an initiation report and $15,000 for update notes, which commenced 09/03/2021.
Hefty fees?!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $47.04K | 11.76M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 25877937 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 832600 | 2 |
View Market Depth
| Last trade - 14.37pm 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |